Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: cc-115 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 827 | 0.91 |
| pathways Reactome | 4 pathways; mostly protein handling | 0.90 |
Knock down and overexpress PRKDC in a dopamine neuron, astrocyte and microglia tri-culture; measure proteasome activity and the load of ubiquitinated protein and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- proteasome activity and the load of ubiquitinated protein
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves proteasome activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PRKDC in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: proteasome activity and the load of ubiquitinated protein; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PRKDC in dopamine neurons, braak+0.00 (p 1.000) → +0.46 (p 0.212)receipt 14770
Swarm cases
receipt 14770: PRKDC in dopamine neurons, braak
- power
- full sample +0.27 (p 0.281, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.35 (p 0.159, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.159, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.38, sign flips 0; without severely affected donors +0.27 (p 0.281, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PRKDC in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts